HER2低表达乳腺癌的临床研究进展

doi:10.11904/j.issn.1002-3070.2022.06.015

摘要/Abstract

摘要： 乳腺癌是全球发病率最高的恶性肿瘤,严重影响女性的健康。人表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)作为乳腺癌重要的治疗靶点,对应的靶向治疗改善了此类患者的预后。在既往的诊治过程中,HER2低表达乳腺癌被归类为HER2阴性乳腺癌的范畴。随着研究的不断深入,发现HER2低表达乳腺癌患者在临床病理、分子生物学特征和生存预后等方面具有一定差异,并且难以从传统的抗HER2治疗中获益。多项研究探索了抗体药物偶联物(Antibody-drug conjugates,ADC)以及其他新型药物在HER2低表达乳腺癌中的疗效及安全性。本文将针对HER2低表达乳腺癌相关研究进展进行综述。

关键词: 乳腺癌, 人表皮生长因子受体2, 低表达, 研究进展

Abstract: Breast cancer is the malignant tumor with the highest incidence in the world,which seriously affects women′s health.As an important therapeutic target for breast cancer,human epidermal growth factor receptor 2(HER2)has improved the prognosis of these patients.In the past diagnosis and treatment process,breast cancer with low HER2 expression was classified as HER2 negative breast cancer.With the deepening research,it is found that breast cancer patients with HER2 low expression have some differences in clinicopathological and molecular biological characteristics,as well as survival prognosis,and are difficult to benefit from traditional anti-HER2 therapy.Several studies have explored the efficacy and safety of antibody-drug conjugates(ADCs)and other new drugs in breast cancer with low HER2 expression.This article will review the research progress of breast cancer with low HER2 expression.

Key words: Breast cancer, HER2, Low expression, Research progress

中图分类号:

R737.9

吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.

WU Ruiyue, ZHU Kaili, YANG Jingru, LING Xiaoling. Clinical research progress of breast cancer with low HER2 expression[J]. Journal of Practical Oncology, 2022, 36(6): 570-575.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/570

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Di FioreP,Pierce JH,Kraus MH,et al.ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells[J].S cience,1987,237(4811):178-182.
3 钟锦绣,李亚梅,关晏星.乳腺癌HER-2胞外配体结合区靶点治疗的研究进展[J].中国肿瘤临床,2013,40(17):1076-1079.
4 Franchet C,Djerroudi L,Maran-Gonzalez A,et al.2021 update of the GEFPICS′ recommendations for HER2 status assessment in invasive breast cancer in France[J].Ann Pathol,2021,41(6):507-520.
5 孙正魁,江泽飞.2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J].中国肿瘤外科杂志,2022,14(3):212-218.
6 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021版)[J].中国癌症杂志,2021,31(10):954-1040.
7 Tarantino P,Hamilton E,Tolaney SM,et al.HER2-low breast cancer:pathological and clinical landscape[J].J Clin Oncol,2020,38(17):1951-1962.
8 Denkert C,Seither F,Schneeweiss A,et al.Clinical and molecular characteristics of HER2-low-positive breast cancer:pooled analysis of individual patient data from four prospective,neoadjuvant clinical trials[J].Lancet Oncol,2021,22(8):1151-1161.
9 Agostinetto E,Rediti M,Fimereli D,et al.HER2-low breast cancer:molecular characteristics and progosis[J].Cancers,2021,13(11):2824.
10 Schettini F,Chic N,Brasó-Maristany F,et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer[J].NPJ Breast Cancer,2021,7(1):1.
11 Modi S,Park H,Murthy RK,et al.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer:results from a phase Ib study[J]J Clin Oncol,2020,38(17):1887-1896.
12 Wolff AC,Hammond MEH,Allison KH,et al.Human epidermal growth factor receptor 2 testing in breast cancer:american society of clinical oncology/college of american pathologists clinical practice guideline focused update[J].J Clin Oncol,2018,36(20):2105-2122.
13 Dieras V,Deluche E,Lusque A,et al.Trastuzumab deruxtecan(T-DXd)for advanced breast cancer patients(ABC),regardless HER2 status:a phase Ⅱ study with biomarkers analysis(AISY)[J].Cancer Res,2022,82(4):67-72.
14 詹晓芬,王少洪,况丽平,等.标本离体固定时间对荧光原位杂交技术检测乳腺润性导管癌HER2基因的影响[J].广西医学,2019,41(8):996-998.
15 Dentro SC,Leshchiner I,Haase K,et al.Characterizing genetic intra-tumor heterogeneity across 2,658 human cancergenomes[J].Cell,2021,184(8):2239-2254.
16 Marchiò C,Annaratone L,Marques A,et al.Evolving concepts in HER2 evaluation in breast cancer:Heterogeneity,HER2-low carcinomas and byond[J].Semin Cancer Biol,2021,72:123-135.
17 Miglietta F,Griguolo G,Bottosso M,et al.Evolution of HER2-low expression from primary to recurrent breast cncer[J].NPJ Breast Cancer,2021,7(1):137.
18 Miglietta F,Griguolo G,Bottosso M,et al.HER2-low-positive breast cancer:evolution from primary tumor to residual disease after neoadjuvant treatment[J].NPJ Breast Cancer,2022,8(1):66.
19 Allison KH,Wolff AC.ERBB2-low breast cancer-is it a fact or fiction,and do we have the right assay[J].JAMA Oncol,2022,8(4):610-611.
20 Grassini D,Cascardi E,Sarotto I,et al.Unusual patterns of HER2 expression in breast cancer:insights and prspectives[J].Pathobiology,2022,89(5):278-296.
21 耿强,钱晓龙,付丽.乳腺癌HER-2检测的概况与进展[J].中国肿瘤临床,2014,41(10):671-674.
22 Asensio AF,Sierra LM,Montes-Bayón M,et al.Sensitive determination of the human epidermal growth factor receptor 2(HER2)by immuno-polymerase chain reaction with inductively coupled plasma-mass spectrometr detection[J].Anal Chim Acta,2019,1090:39-46.
23 Fernandez AI,Liu M,Bellizzi A,et al.Examination of low ERBB2 protein expression in brast cancer tissue[J].JAMA Oncol,2022,8(4):1-4.
24 Zhang G,Ren C,Li C,et al.Distinct clinical and somatic mutational features of breast tumors with high-,low-,or non-expressing human epidermal growth fator receptor 2 status[J].BMC Med,2022,20(1):142.
25 Zhang H,Katerji H,Turner BM,et al.HER2-low breast cancers:incidence,HER2 staining patterns,clinicopathologic features,MammaPrint and BluePrint genomi profiles[J].Mod Pathol,Inc,2022,35(8):1075-1082.
26 Jacot W,Maran-Gonzalez A,Massol O,et al.Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlationwith other biomarkers[J].Cancers,2021,13(23):6059.
27 Pondé N,Aftimos P,Piccart M.Antibody-drug conjugates in breast cancer:a comprehensve review[J].Curr Treat Options Oncol,2019,20(5):37.
28 Xu ZY,Guo DD,Jiang ZL,et al.Novel HER2-targeting antibody-drug conjugates of Trastuzumab beyond T-DM1 in breast cancer:Trastuzumab Deruxtecan(DS-8201a)and(Vic-)Trastuzumab Ducarmazine(SYD985)[J].Eur J Med Chem,2019,183:111682.
29 Press MF,Finn RS,Cameron D,et al.HER2 gene amplification,HER2 and epidermal growth factor receptor mRNA and protein expression,and lapatinib efficacy in women with metastatic brast cancer[J].Clin Cancer Res,2008,14(23):7861-7870.
30 Modi S,Jacot W,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J].N Engl J Med,2022,387(1):9-20.
31 Banerji U,Herpen CML,Saura C,et al.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer:a phase 1 dose-escalation and dos-expansion study[J].Lancet Oncol,2019,20(8):1124-1135.
32 Xu Y,Wang Y,Gong J,et al.Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive avanced solid tumors[J].Gastric Cancer,2021,24(4):913-925.
33 Li L,Xu MZ,Wang L,et al.Conjugating MMAE to a novel anti-HER2 antibody for selective targeted dlivery[J].Eur Rev Med Pharmacol Sci,2020,24(24):12929-12937.
34 Shi F,Liu Y,Zhou X,et al.Disitamab vedotin:a novel antibody-drug conugates for cancer therapy[J].Drug Deliv,2022,29(1):1335-1344.
35 Schmid P,Im SA,Armstrong A,et al.BEGONIA:Phase 1b/2 study of durvalumab(D)combinations in locally advanced/metastatic triple-negative breast cancer(TNBC)-initial results from arm 1,d+paclitaxel(P),and arm 6,d+trasuzumab deruxtecan(T-DXd)[J].J Clin Oncol,2021,39(15):15-21.
36 Hamilton EP,Shapiro CL,Boni V,et al.Primary analysis from DS8201-A-U105:a 2-part,open label,phase Ib trial assessing trastuzumab deruxtecan(T-DXd)with nivolumab(nivo)in patients(pts)with HER2-xpressing advanced breast cancer[J].Ann Oncol,2022,33:194-223.
37 Segués A,Huang S,Sijts A,et al.Opportunities and challenges ofbi-specific antibodies[J].Int Rev Cell Mol Biol,2022,369:45-70.
38 Zhang J,Ji D,Cai L,et al.First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer:rsults from a phase I study[J].Clin Cancer Res,2022,28(4):618-628.
39 Bartsch R,Bergen E.ASCO 2018:highlights in HER2-positive metastatic breast cancer[J].Memo,2018,11(4):280-283.
40 Akbari V,Chou CP,Abedi D.New insights into affinity proteins for HER2-targeted therapy:beyond trastuzumab[J].Biochim Biophys Acta Rev Cancer,2020,1874(2):1888448.
41 Hamblett KJ,Hammond PW,Barnscher SD,et al.ZW49,a HER2-targeted biparatopic antibody-drug conjugate for the tratment of HER2-expressing cancers[J].Cancer Res,2018,78(13):69-73.
42 Burstein HJ.The distinctive nature of HER2-positive breast cancers[J].N Engl J Med,2005,353(16):1652-1654.
43 Schneble EJ,Berry JS,Trappey FA,et al.The HER2 peptide nelipepimut-S(E75)vaccine(NeuVax^TM)in breast cancer patients at risk for recurrence:correlation of immunlogic data with clinical response[J].Immunotherapy,2014,6(5):519-531.
44 Gall VA,Philips AV,Qiao N,et al.Trastuzumab increases HER2 uptake and crss-presentation by dendritic cells[J].Cancer Res,2017,77(19):5374-5383.
45 Mittendorf EA,Clifton GT,Holmes JP,et al.Final report of the phase Ⅰ/Ⅱ clinical trial of the E75(nelipepimut-S)vaccine with booster inoculations to prevent disease recurrenc in high-risk breast cancer patients[J].Ann Oncol,2014,25(9):1735-1742.
46 Mittendorf EA,Lu B,Melisko M,et al.Efficacy and safety analysis of nelipepimut-s vaccine to prevent breast cancer recurrence:a randomized,multicnter,phase Ⅲ Clinical trial[J].Clin Cancer Res,2019,25(14):4248-4254.

[1]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[2]	陈俊慧, 刘思雨, 贺长军. RUNX1在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 576-579.
[3]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.
[4]	康子曼, 杨聃琳, 孙建男. 乳腺MRI图像纹理分析在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 472-476.
[5]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.
[6]	陈嘉一, 白彦灵. 乳腺癌患者体重指数及体位固定方式对保乳术后调强放射治疗摆位误差的影响[J]. 实用肿瘤学杂志, 2022, 36(4): 327-331.
[7]	赵丹妮, 闫石, 蔡莉. 乳腺癌随访和药物副作用管理策略的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 369-373.
[8]	宗禹萱, 庞达. 热休克蛋白90在乳腺癌发生发展及治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 381-385.
[9]	杨子涵, 许守平, 庞达. 乳腺癌发生腋窝外三角组织转移特点与影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(3): 226-232.
[10]	何伟丹, 李志高. FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后[J]. 实用肿瘤学杂志, 2022, 36(3): 233-238.
[11]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[12]	杨姝娅, 刘文慧, 骆耐香. UCA1在乳腺癌中的研究现状和应用展望[J]. 实用肿瘤学杂志, 2022, 36(3): 263-267.
[13]	刘婉莹, 庞达. 乳腺浸润性微乳头状癌转移机制的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 268-272.
[14]	陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.
[15]	孙元元, 张苧之, 曹孟儒. 乳腺癌肺转移机制及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(2): 173-177.